G. Rébék-Nagy, V. Warta

Of the language teaching trends of the 20th century the social demands for Teaching English for Medical Purposes (TEMP) has markedly delineated. Simultaneously with employing English for Medical Purposes (EMP) interpreters and translators, the need for medical professionals aware of the register, discourse and major genres of the international biomedical community tends to increase even more rapidly. The obvious explanation to this lies in the advantage that through their professional socialization these health care providers possess the kind of background knowledge that underpins a special purpose language use.
The limited length of the present study gives an opportunity for only presenting the descriptors selected at C1 level from CEFR.
A further step is to set up a team of assessors whose members need to be trained. The last phase of standardization is the most time-consuming and demanding internal and external validation which are hoped to be carried out using the resources of an EU grant.
The finalized set of EMP tests will be made available in and outside the EU, with special regard to Japan, China and South Korea and Serbia in order that medical universities and faculties in these countries can use it at their own discretion as a professional language output. This step may lead to the standardization of the communication within the international biomedical discourse community as well as the doctor-patient interaction.

Landherr L.

Standard treatment of advanced colorectal cancer (CRC) contains some kind of luoropyrimidine, oxaliplatin or irinotecan. Thanks to the supplementation of chemotherapy with targeted biological agents (bevacizumab, cetuximab, panitumumab), results improved further and today survival exceeds 2 years even in the case of advanced tumors. Moreover, hepatic metastases may become operable after effective therapy, thus certain patients may recover completely. Genetic characteristics of tumors significantly affect both response to treatment and toxicity, therefore, on the basis of such characteristics, it is possible to select those patients that will respond differently to therapy. Thus toxicity associated with unnecessary (and very expensive) treatment can be avoided and patients benefiting the most from therapy can be selected.
In this publication, the author provides a review of biomarkers related to drugs involved in CRC treatment and influencing the activity thereof.